Skip to main content

Table 1 Information of the LGSC cell cultures used in this study

From: Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

Patient number Sample name Pathology at collection Treatment status at collection Cell culture type % genome change by WES Total number non-synonymous AA changes KRAS/NRAS/BRAF mutation status CNV changes affecting KRAS/NRAS/BRAF genes Selumetinib IC50 (μM) Trametinib IC50 (μM) MEKi drug response
1 iOvCa241 Advanced LGSC Post chemotherapy Cell line 34 106 KRAS (G12D) KRAS: allelic imbalance, CN gain 0.30 ≤ 0.05 Sensitive
2 VOA-1312 Advanced LGSC Treatment naïve Cell line 35 Undetermined KRAS (G12V) a KRAS: allelic imbalance, CN gain 0.50 ≤ 0.05 Sensitive
3 VOA-8862 Advanced LGSC with MP Treatment naïve Cell line 66 24 KRAS (G12D), NRAS (C118Y) KRAS: allelic imbalance, CN gain; NRAS: CN loss; BRAF: alellic imbalance, CN gain 5.00 ≤ 0.05 Sensitive
4 VOA-9164 Recurrent LGSC Post anti-hormone therapy Cell line 51 33 KRAS (G12V) KRAS: allelic imbalance, CN gain; NRAS: CN loss; BRAF: high CN gain 0.30 ≤ 0.05 Sensitive
5 VOA-1056 Advanced MPSBT with invasive implants Treatment naïve Cell line 1 75 NRAS (Q61R) NRAS: CN gain 0.30 ≤ 0.05 Resistant
VOA-3993 Recurrent LGSC Post anti-hormone therapy Cell line 16 84 NRAS (Q61R) KRAS: allelic imbalance, CN gain; NRAS: CN gain 5.42 ≤ 0.05 Resistant
6 VOA-3448 Recurrent LGSC with MP Post chemotherapy and anti-hormone therapy Cell line 39 78 Wild type BRAF: CN gain 0.58 ≤ 0.05 Resistant
VOA-3723 Recurrent LGSC with MP Post chemotherapy and anti-hormone therapy Cell line 40 96 Wild type None 1.00 ≤ 0.05 Resistant
7 VOA-4627 Recurrent LGSC Post chemotherapy, anti-hormone therapy, and targeted therapy Cell line 56 111 Wild type KRAS: CN gain; BRAF: LOH 8.75 0.08 Resistant
VOA-4698 Recurrent LGSC Post chemotherapy, anti-hormone therapy, and targeted therapy Cell line 50 110 Wild type KRAS: CN gain; NRAS: CN gain; BRAF: LOH 11.67 0.08 Resistant
8 VOA-6406 Advanced LGSC Post chemotherapy Cell line 23 80 NRAS (Q61R) NRAS: CN gain 0.64 ≤ 0.05 Resistant
9 VOA-6857 Recurrent LGSC Post chemotherapy, anti-hormone therapy, and MEKi therapy Transient culture 27 83 Wild type None n/a n/a n/a
10 VOA-7604 Advanced LGSC with SBT Treatment naïve Transient culture 25 61 Wild type KRAS: allelic imbalance, CN gain n/a n/a n/a
11 VOA-6800 Advanced LGSC Post chemotherapy Transient culture 29 68 BRAF (D594G) None n/a n/a n/a
  1. The same typeface (roman or italic) has been used to help group cell lines from the same patient
  2. LGSC low grade serous ovarian carcinoma, MP micropapillary, MPSBTmicropapillary serous bordeline ovarian tumor, SBT serous borderline ovarian tumor, WES whole-exome sequencing analysis, CNV gene copy number variation, AA aminoacids, IC50 50% cell inhibitory concentration
  3. aNo buffy coat available; somatic from germline mutations are undiscernable
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us